Month of follow-up	Year period of ART initiation	Mean Diff.	95% CI	p value
3	2003–05	ref
	2006–09	10	(4, 15)	0.001
	2010–13	18	(12, 24)	<0.001
6	2003–05	ref
	2006–09	5	(−1, 11)	0.093
	2010–13	15	(9, 22)	<0.001
9	2003–05	ref
	2006–09	2	(−4, 9)	0.497
	2010–13	13	(6, 19)	<0.001
12	2003–05	ref
	2006–09	1	(−6, 7)	0.856
	2010–13	10	(4, 16)	0.002
15	2003–05	ref
	2006–09	0	(−6, 6)	0.979
	2010–13	8	(1, 14)	0.017
18	2003–05	ref
	2006–09	0	(−6, 6)	0.888
	2010–13	6	(0, 12)	0.067
21	2003–05	ref
	2006–09	1	(−5, 8)	0.666
	2010–13	5	(−2, 12)	0.132
24	2003–05	ref
	2006–09	3	(−4, 9)	0.425
	2010–13	5	(−2, 12)	0.126
27	2003–05	ref
	2006–09	4	(−3, 10)	0.233
	2010–13	7	(0, 14)	0.046
30	2003–05	ref
	2006–09	5	(−1, 11)	0.128
	2010–13	10	(3, 18)	0.004
33	2003–05	ref
	2006–09	6	(−2, 13)	0.150
	2010–13	16	(7, 24)	<0.001
36	2003–05	ref
	2006–09	5	(−6, 17)	0.354
	2010–13	23	(10, 36)	<0.001

Note: Multivariate model adjusts for age at ART initiation, gender, HIV mode of exposure, pre-ART HIV viral load, pre-ART CD4 count, first ART regimen, hepatitis B co-infection, hepatitis C co-infection and clinical site.